Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$2.23 -0.9%	$1.67	$1.20 ▼ $6.75	$126.80M	2.63	1.51 million shs	945,891 shs
OLMA Olema Pharmaceuticals	$5.32 +0.4%	$4.45	$2.86 ▼ $16.62	$364M	2.03	854,527 shs	361,610 shs
RGNX REGENXBIO	$8.68 -3.2%	$7.88	$5.04 ▼ $15.36	$435.39M	1.11	893,192 shs	830,369 shs
TECX Tectonic Therapeutic	$21.51 -4.0%	$19.37	$13.70 ▼ $61.07	$418.28M	3.44	173,979 shs	110,340 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	-0.89%	+10.95%	+31.18%	+10.95%	-53.05%
OLMA Olema Pharmaceuticals	+0.38%	+5.56%	+3.10%	+21.74%	-44.87%
RGNX REGENXBIO	-3.23%	-10.61%	-9.68%	+32.12%	-38.48%
TECX Tectonic Therapeutic	-3.97%	-0.65%	+3.12%	-14.91%	+2,150,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BDTX Black Diamond Therapeutics	3.5621 of 5 stars	3.5	4.0	0.0	3.3	2.5	1.3
OLMA Olema Pharmaceuticals	1.943 of 5 stars	3.5	1.0	0.0	2.8	2.5	0.0
RGNX REGENXBIO	4.2363 of 5 stars	3.4	1.0	4.6	3.5	3.3	0.6
TECX Tectonic Therapeutic	3.0234 of 5 stars	3.6	1.0	0.0	2.6	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDTX Black Diamond Therapeutics	3.00	Buy	$14.60	554.71% Upside
OLMA Olema Pharmaceuticals	3.00	Buy	$24.50	360.53% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	264.34% Upside
TECX Tectonic Therapeutic	3.14	Buy	$79.20	268.20% Upside

Current Analyst Ratings Breakdown

Latest BDTX, TECX, RGNX, and OLMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	TECX Tectonic Therapeutic	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$51.00 ➝ $85.00
5/14/2025	OLMA Olema Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $18.00
5/14/2025	OLMA Olema Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $22.00
4/28/2025	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/21/2025	TECX Tectonic Therapeutic	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$51.00
4/17/2025	RGNX REGENXBIO	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $12.00
3/28/2025	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$30.00 ➝ $28.00
3/21/2025	TECX Tectonic Therapeutic	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$112.00 ➝ $101.00
3/20/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00 ➝ $52.00
3/19/2025	BDTX Black Diamond Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
3/19/2025	OLMA Olema Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $25.00

(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDTX Black Diamond Therapeutics	$70M	1.81	N/A	N/A	$2.26 per share	0.99
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$4.61 per share	N/A
RGNX REGENXBIO	$156.72M	2.78	N/A	N/A	$7.09 per share	1.22
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$2.13 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDTX Black Diamond Therapeutics	-$82.44M	$0.06	N/A	N/A	N/A	N/A	-68.08%	-49.65%	8/5/2025 (Estimated)
OLMA Olema Pharmaceuticals	-$96.65M	-$2.01	N/A	N/A	N/A	N/A	-53.56%	-47.86%	8/5/2025 (Estimated)
RGNX REGENXBIO	-$263.49M	-$3.11	N/A	N/A	N/A	-283.19%	-70.65%	-41.68%	8/7/2025 (Estimated)
TECX Tectonic Therapeutic	$12.16M	-$7.31	N/A	N/A	N/A	N/A	-35.53%	-31.97%	8/13/2025 (Estimated)

Latest BDTX, TECX, RGNX, and OLMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	OLMA Olema Pharmaceuticals	-$0.49	-$0.36	+$0.13	-$0.36	N/A	N/A
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
5/8/2025	Q1 2025	TECX Tectonic Therapeutic	-$1.10	-$0.93	+$0.17	-$0.93	N/A	N/A
3/20/2025	Q4 2024	TECX Tectonic Therapeutic	-$1.39	-$0.84	+$0.55	-$0.84	N/A	N/A
3/18/2025	Q4 2024	OLMA Olema Pharmaceuticals	-$0.63	-$0.51	+$0.12	-$0.51	N/A	N/A
3/13/2025	Q4 2024	RGNX REGENXBIO	-$1.27	-$1.01	+$0.26	-$1.01	$23.70 million	$21.21 million
3/6/2025	Q4 2024	BDTX Black Diamond Therapeutics	-$0.31	-$0.28	+$0.03	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDTX Black Diamond Therapeutics	N/A	5.55	5.55
OLMA Olema Pharmaceuticals	N/A	7.10	7.10
RGNX REGENXBIO	N/A	3.05	3.05
TECX Tectonic Therapeutic	N/A	9.39	9.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDTX Black Diamond Therapeutics	95.47%
OLMA Olema Pharmaceuticals	91.78%
RGNX REGENXBIO	88.08%
TECX Tectonic Therapeutic	62.63%

Insider Ownership

Company	Insider Ownership
BDTX Black Diamond Therapeutics	8.87%
OLMA Olema Pharmaceuticals	19.40%
RGNX REGENXBIO	12.79%
TECX Tectonic Therapeutic	38.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDTX Black Diamond Therapeutics	90	56.86 million	51.57 million	Optionable
OLMA Olema Pharmaceuticals	70	68.42 million	46.18 million	Optionable
RGNX REGENXBIO	370	50.16 million	43.04 million	Optionable
TECX Tectonic Therapeutic	120	18.67 million	13.40 million	N/A

BDTX, TECX, RGNX, and OLMA Headlines

Recent News About These Companies

Tectonic Therapeutic Reports Q1 2025 Financial Results

May 31 at 12:07 AM | tipranks.com

Woodline Partners LP Has $6.01 Million Holdings in Tectonic Therapeutic (NASDAQ:TECX)

May 26, 2025 | marketbeat.com

29,702 Shares in Tectonic Therapeutic (NASDAQ:TECX) Purchased by Jane Street Group LLC

May 22, 2025 | marketbeat.com

Promising Phase 1b Results and Market Potential Drive Buy Rating for Tectonic Therapeutic’s TX45

May 22, 2025 | tipranks.com

Soleus Capital Management L.P. Makes New Investment in Tectonic Therapeutic (NASDAQ:TECX)

May 21, 2025 | marketbeat.com

Tectonic Therapeutic Announces Phase 1b Trial Results

May 19, 2025 | tipranks.com

Promising Phase 1b Results and Favorable Safety Profile Justify Buy Rating for Tectonic Therapeutic

May 19, 2025 | tipranks.com

Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Amgen (AMGN)

May 17, 2025 | theglobeandmail.com

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in ...

May 17, 2025 | gurufocus.com

Tectonic Therapeutic Reports Positive Phase 1b Results for TX45 in Group 2 Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction

May 17, 2025 | quiverquant.com

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure

May 17, 2025 | investing.com

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025

May 17, 2025 | globenewswire.com

Paradigm Biocapital Advisors LP Takes $22.40 Million Position in Tectonic Therapeutic (NASDAQ:TECX)

May 16, 2025 | marketbeat.com

Tectonic Therapeutic (NASDAQ:TECX) Receives Consensus Recommendation of "Buy" from Analysts

May 16, 2025 | marketbeat.com

Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High?

May 13, 2025 | zacks.com

Tectonic Therapeutic (NASDAQ:TECX) Announces Earnings Results, Beats Expectations By $0.17 EPS

May 12, 2025 | marketbeat.com

Farallon Capital Management LLC Boosts Holdings in Tectonic Therapeutic (NASDAQ:TECX)

May 11, 2025 | marketbeat.com

Balyasny Asset Management L.P. Has $11.40 Million Stock Holdings in Tectonic Therapeutic (NASDAQ:TECX)

May 11, 2025 | marketbeat.com

Tectonic Therapeutic (NASDAQ:TECX) Shares Purchased by Barclays PLC

May 9, 2025 | marketbeat.com

Promising Potential of Tectonic Therapeutic’s TX45: Buy Rating Supported by Positive Phase Ib Trial Results and Phase II Prospects

May 8, 2025 | tipranks.com

Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX, TECX, RGNX, and OLMA Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

$2.23 -0.02 (-0.89%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$2.24 +0.01 (+0.45%)

As of 05/30/2025 07:56 PM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Olema Pharmaceuticals NASDAQ:OLMA

$5.32 +0.02 (+0.38%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$5.26 -0.06 (-1.03%)

As of 05/30/2025 07:34 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

REGENXBIO NASDAQ:RGNX

$8.68 -0.29 (-3.23%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$8.92 +0.24 (+2.81%)

As of 05/30/2025 07:48 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Tectonic Therapeutic NASDAQ:TECX

$21.51 -0.89 (-3.97%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$21.52 +0.00 (+0.02%)

As of 05/30/2025 04:04 PM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time